Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,623 JPY | +0.09% | -2.43% | -1.31% |
Apr. 29 | AstraZeneca makes progress with Truqap and Enhertu cancer treatments | AN |
Apr. 25 | AstraZeneca upbeat as cancer drugs underpin sales growth | AN |
Sales 2024 * | 201B 1.31B | Sales 2025 * | 198B 1.3B | Capitalization | 356B 2.33B |
---|---|---|---|---|---|
Net income 2024 * | 52.51B 343M | Net income 2025 * | 52.26B 341M | EV / Sales 2024 * | 1.78 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.79 x |
P/E ratio 2024 * |
7.44
x | P/E ratio 2025 * |
7.18
x | Employees | 864 |
Yield 2024 * |
5.44% | Yield 2025 * |
5.59% | Free-Float | 46.97% |
1 day | +0.09% | ||
1 week | -2.43% | ||
Current month | -5.45% | ||
1 month | -1.52% | ||
3 months | -10.17% | ||
6 months | +31.63% | ||
Current year | -1.31% |
Managers | Title | Age | Since |
---|---|---|---|
Akihiko Ishihara
CEO | Chief Executive Officer | 61 | 86-03-31 |
Chairman | 71 | 77-03-31 | |
Sou Busujima
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 71 | 77-03-31 | |
Akihiko Ishihara
CEO | Chief Executive Officer | 61 | 86-03-31 |
Ichiro Tomiyama
COO | Chief Operating Officer | 66 | 86-10-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.78% | 9 M€ | +21.43% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-02 | 1,623 | +0.09% | 1,231,600 |
24-05-01 | 1,622 | -5.53% | 2,200,200 |
24-04-30 | 1,716 | +3.19% | 2,269,500 |
24-04-26 | 1,664 | +1.87% | 1,546,700 |
24-04-25 | 1,633 | -1.98% | 772,100 |
Delayed Quote Japan Exchange, May 02, 2024 at 02:00 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.31% | 2.31B | |
+13.21% | 8.24B | |
+9.43% | 709M | |
-28.66% | 684M | |
+31.17% | 377M | |
+4.63% | 337M | |
-11.45% | 253M | |
+6.00% | 170M | |
+27.47% | 102M | |
-24.07% | 67.22M |
- Stock Market
- Equities
- 6417 Stock